EQL Pharma AB (publ) has entered into an exclusive license agreement with a large pharmaceutical company for its product Mellozzan (melatonin) for Turkiye and Kazakhstan. Mellozzan contains the sleep hormone melatonin and is indicated for children who have ADHD and suffer from sleep difficulties, where so-called sleep hygiene measures have not helped. Mellozzan will probably be the first melatonin product in Turkiye and Kazakhstan with that paediatric indication.

The drug is also indicated for the short-term treatment of jet lag in adults. The agreement includes a so-called tech transfer to produce Mellozzan in a factory in Turkiye, as local production is a requirement from the Turkish authorities. The agreement also includes a small license fee and a single-digit royalty on all sales.